Abstract
Rising neurodegenerative disease prevalence and expanding patent populations -
where are the best opportunities and how can you unlock these? Our new report
- World Neurodegenerative Diseases Market 2009-2024 - explains.
The ageing of the baby-boom generation, combined with new and emerging
treatments for neurodegenerative disorders - including multiple sclerosis,
Alzheimer' s disease and Parkinson' s disease - will lead to further expansion
of the neurodegenerative therapies market. Increasing disease prevalence and a
robust pipeline make that sector dynamic and highly promising for
pharmaceutical and biotechnology companies worldwide. Our new report - World
Neurodegenerative Diseases Market 2009-2024 - explains why, revealing where
the most-exciting developments will lie from the present onwards.
This report examines markets for treating the following disorders in particular:
- Parkinson' s disease
- Alzheimer' s disease
- Multiple sclerosis
- Amyotrophic lateral sclerosis
- Neuropathies.
Also covered are the following neurodegenerative disorders:
- Huntington' s disease
- Prion diseases.
What types of therapeutic agent are likely to enter the market from 2009
onwards, and will they hold the potential to dominate this market area? Where
will the best commercial opportunities lie from 2009 onwards? What are the
most-crucial drivers and restraints in this market? This report will provide
you with the information that you need to understand current trends and future
directions in neurodegenerative disorder therapies. In particular, we discuss
prospects for the following products in detail:
- Sifrol
- Stalevo
- Requip
- Aricept
- Namenda
- Exelon
- Reminyl
- Avonex
- Copaxone
- Rebif
- Betaferon
- Rilutek.
In our pipeline analyses we include emerging therapeutics such as stem cells,
gene therapy and monoclonal antibodies, among other prominent developments.
Detailed analysis of the neurodegenerative disorders market sector
World Neurodegenerative Diseases Market 2009-2024 examines that sector
critically, through a comprehensive review of information sources, both
primary and secondary. This report provides detailed sales forecasts, market
share analyses, discussions of pipeline developments and analyses of
commercial drivers and restraints, including a SWOT analysis. There are 63
tables and figures included, as well as three full interviews with relevant
authorities. The result is a comprehensive market- and industry-centred study,
with detailed analyses and informed opinion to benefit your work.
Research interviews from our comprehensive survey
This report contains visiongain interviews with the following relevant experts:
- 1) Dr Johan Luthman, former Global Head of Exploratory Medicine
(Neurology, Autoimmune & Inflammatory Diseases), Merck Serono
- 2) Dr Allan Tobin, Senior Scientific Advisor to the CHDI Foundation
- 3) Professor Peter Jenner, founder and Chief Science Officer, Proximagen
Neurosciences, and Professor in Pharmacology, King' s College, University of
London.
Why you should buy World Neurodegenerative Diseases Market 2009-2024
In this report you will receive the following benefits in particular:
- You will assess the current market for neurodegenerative disease
therapeutics
- You will review the overall neurodegenerative disease therapeutics market,
including a global sales forecast for 2009 to 2024
- You will receive sales forecasts for neurodegenerative disorder submarkets
from 2009 to 2024, with detailed discussions
- You will receive sales forecasts for leading products from 2009 to 2024,
with detailed discussions of market potential and competition
- You will receive sales forecasts for leading geographical markets from
2009 to 2024, with informed discussion
- You will examine commercial drivers and restraints in depth
- You will discover the most-exciting pipeline developments in the sector,
with informed commentary
- You will discover expert opinions from our original survey of the sector,
with prominent contributions from industry and academia.
You can obtain this report today
Nobody with an interest in the neurodegenerative diseases sector can afford to
overlook this new market study. We predict that total revenues will increase
throughout our forecast period, 2009 to 2024. With rising disease prevalence
and expanding patient populations - coupled with high economic and social
costs of those diseases - this therapeutic area holds significant potential
for revenue growth. Do you want to harness those opportunities? You can stay
ahead by ordering this report today
| 
View Cart
